摘要
目的:研究依鲁替尼(ibrutinib)在体外对伯基特淋巴瘤细胞株Namawal的作用,探讨其可能的分子机制。方法:应用CCK8法,细胞周期分析法检测依鲁替尼作用于Namawal细胞株后,对其增殖、细胞周期等细胞生物学的影响;应用免疫荧光电镜观察药物作用该细胞株后48H细胞核变化;应用免疫印迹法检测ibrutinib作用于Namawal后BTK信号通路相关蛋白的变化。结果:经依鲁替尼处理后的Namawal细胞增殖受到明显抑制;依鲁替尼下调BTK信号通路上相关蛋白活性。结论:依鲁替尼通过抑制p-BTK活性抑制细胞增殖,诱导肿瘤细胞凋亡,是治疗Burkitt淋巴瘤的潜在新药。
Objective：To investigate the effect of ibrutinib on Burkitt＇s Lymphoma Namawal cell line and discuss its potential molecular mechanism. Methods：The viability of Namawal cells was observed by CCK8.Cell cycle arrest was observed by cell cycle analysis. The morphology of the nucleus was observed by immunofluorescence electron microscopy.The expressions of the proteins associated with BTK signaling pathway was detected by Western blot. Results：Compared with untreated cells, ibrutinib significantly inhibited the proliferation of Namawal cells.It downregulated the expression of the proteins associated with BTK signaling pathway. Conclution：Ibrutinib inhibits the proliferation of Namawal cells and induce apoptosis by downregulating p-BTK.Ibrutinib might be a potential new drug for anti-Burkitt＇s Lymphoma.
出处
《交通医学》
2016年第1期24-28,共5页
Medical Journal of Communications
基金
国家自然科学基金项目(81101786)
国家自然科学基金(81570184)
南通大学研究生科技创新计划项目基金(YKS14022)
